Cargando…

ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification

ABSTRACT: Several studies have searched for new antigens to produce pneumococcal vaccines that are more effective and could provide broader coverage, given the great number of serotypes causing pneumococcal diseases. One of the promising subunit vaccine candidates is untagged recombinant pneumococca...

Descripción completa

Detalles Bibliográficos
Autores principales: Cardoso, Valdemir M., Paredes, Sheyla A. H., Campani, Gilson, Gonçalves, Viviane M., Zangirolami, Teresa C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755982/
https://www.ncbi.nlm.nih.gov/pubmed/35024919
http://dx.doi.org/10.1007/s00253-022-11758-9
_version_ 1784632484034510848
author Cardoso, Valdemir M.
Paredes, Sheyla A. H.
Campani, Gilson
Gonçalves, Viviane M.
Zangirolami, Teresa C.
author_facet Cardoso, Valdemir M.
Paredes, Sheyla A. H.
Campani, Gilson
Gonçalves, Viviane M.
Zangirolami, Teresa C.
author_sort Cardoso, Valdemir M.
collection PubMed
description ABSTRACT: Several studies have searched for new antigens to produce pneumococcal vaccines that are more effective and could provide broader coverage, given the great number of serotypes causing pneumococcal diseases. One of the promising subunit vaccine candidates is untagged recombinant pneumococcal surface protein A (PspA4Pro), obtainable in high quantities using recombinant Escherichia coli as a microbial factory. However, lipopolysaccharides (LPS) present in E. coli cell extracts must be removed, in order to obtain the target protein at the required purity, which makes the downstream process more complex and expensive. Endotoxin-free E. coli strains, which synthesize a nontoxic mutant LPS, may offer a cost-effective alternative way to produce recombinant proteins for application as therapeutics. This paper presents an investigation of PspA4Pro production employing the endotoxin-free recombinant strain ClearColi® BL21(DE3) with different media (defined, auto-induction, and other complex media), temperatures (27, 32, and 37 °C), and inducers. In comparison to conventional E. coli cells in a defined medium, ClearColi presented similar PspA4Pro yields, with lower productivities. Complex medium formulations supplemented with salts favored PspA4Pro yields, titers, and ClearColi growth rates. Induction with isopropyl-β-d-thiogalactopyranoside (0.5 mM) and lactose (2.5 g/L) together in a defined medium at 32 °C, which appeared to be a promising cultivation strategy, was reproduced in 5 L bioreactor culture, leading to a yield of 146.0 mg PspA4Pro/g dry cell weight. After purification, the cell extract generated from ClearColi led to 98% purity PspA4Pro, which maintained secondary structure and biological function. ClearColi is a potential host for industrial recombinant protein production. KEY POINTS: • ClearColi can produce as much PspA4Pro as conventional E. coli BL21(DE3) cells. • 10.5 g PspA4Pro produced in ClearColi bioreactor culture using a defined medium. • Functional PspA4Pro (98% of purity) was obtained in ClearColi bioreactor culture. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00253-022-11758-9.
format Online
Article
Text
id pubmed-8755982
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-87559822022-01-13 ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification Cardoso, Valdemir M. Paredes, Sheyla A. H. Campani, Gilson Gonçalves, Viviane M. Zangirolami, Teresa C. Appl Microbiol Biotechnol Biotechnological Products and Process Engineering ABSTRACT: Several studies have searched for new antigens to produce pneumococcal vaccines that are more effective and could provide broader coverage, given the great number of serotypes causing pneumococcal diseases. One of the promising subunit vaccine candidates is untagged recombinant pneumococcal surface protein A (PspA4Pro), obtainable in high quantities using recombinant Escherichia coli as a microbial factory. However, lipopolysaccharides (LPS) present in E. coli cell extracts must be removed, in order to obtain the target protein at the required purity, which makes the downstream process more complex and expensive. Endotoxin-free E. coli strains, which synthesize a nontoxic mutant LPS, may offer a cost-effective alternative way to produce recombinant proteins for application as therapeutics. This paper presents an investigation of PspA4Pro production employing the endotoxin-free recombinant strain ClearColi® BL21(DE3) with different media (defined, auto-induction, and other complex media), temperatures (27, 32, and 37 °C), and inducers. In comparison to conventional E. coli cells in a defined medium, ClearColi presented similar PspA4Pro yields, with lower productivities. Complex medium formulations supplemented with salts favored PspA4Pro yields, titers, and ClearColi growth rates. Induction with isopropyl-β-d-thiogalactopyranoside (0.5 mM) and lactose (2.5 g/L) together in a defined medium at 32 °C, which appeared to be a promising cultivation strategy, was reproduced in 5 L bioreactor culture, leading to a yield of 146.0 mg PspA4Pro/g dry cell weight. After purification, the cell extract generated from ClearColi led to 98% purity PspA4Pro, which maintained secondary structure and biological function. ClearColi is a potential host for industrial recombinant protein production. KEY POINTS: • ClearColi can produce as much PspA4Pro as conventional E. coli BL21(DE3) cells. • 10.5 g PspA4Pro produced in ClearColi bioreactor culture using a defined medium. • Functional PspA4Pro (98% of purity) was obtained in ClearColi bioreactor culture. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00253-022-11758-9. Springer Berlin Heidelberg 2022-01-13 2022 /pmc/articles/PMC8755982/ /pubmed/35024919 http://dx.doi.org/10.1007/s00253-022-11758-9 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Biotechnological Products and Process Engineering
Cardoso, Valdemir M.
Paredes, Sheyla A. H.
Campani, Gilson
Gonçalves, Viviane M.
Zangirolami, Teresa C.
ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification
title ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification
title_full ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification
title_fullStr ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification
title_full_unstemmed ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification
title_short ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification
title_sort clearcoli as a platform for untagged pneumococcal surface protein a production: cultivation strategy, bioreactor culture, and purification
topic Biotechnological Products and Process Engineering
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755982/
https://www.ncbi.nlm.nih.gov/pubmed/35024919
http://dx.doi.org/10.1007/s00253-022-11758-9
work_keys_str_mv AT cardosovaldemirm clearcoliasaplatformforuntaggedpneumococcalsurfaceproteinaproductioncultivationstrategybioreactorcultureandpurification
AT paredessheylaah clearcoliasaplatformforuntaggedpneumococcalsurfaceproteinaproductioncultivationstrategybioreactorcultureandpurification
AT campanigilson clearcoliasaplatformforuntaggedpneumococcalsurfaceproteinaproductioncultivationstrategybioreactorcultureandpurification
AT goncalvesvivianem clearcoliasaplatformforuntaggedpneumococcalsurfaceproteinaproductioncultivationstrategybioreactorcultureandpurification
AT zangirolamiteresac clearcoliasaplatformforuntaggedpneumococcalsurfaceproteinaproductioncultivationstrategybioreactorcultureandpurification